柠檬酸铁降低慢性肾脏病小鼠模型FGF23水平并改善肾脏与心脏功能
该研究在Col4a3敲除进行性CKD小鼠模型中比较柠檬酸铁与矿物质充足对照饮食的作用。柠檬酸铁无论起始时机均纠正缺铁和贫血,早期起始还降低血磷、FGF23、肾纤维化和蛋白尿,改善肾功能并延长寿命。
要点
- 柠檬酸铁可纠正CKD小鼠缺铁和贫血,与治疗起始时机无关。
- 早期CKD起始柠檬酸铁可降低血清磷酸盐和FGF23水平。
- 早期起始柠檬酸铁减缓CKD进展、改善心脏功能并延长生存。
核心结论
- 在 murine CKD 早期起始柠檬酸铁可降低FGF23、减缓CKD进展、改善心脏功能并显著改善生存。
研究设计与样本
- 研究使用Col4a3敲除进行性CKD小鼠模型与年龄匹配野生型小鼠比较柠檬酸铁与矿物质充足对照饮食。
- 敲除小鼠于6周龄已患明显CKD时起始柠檬酸铁4周,或于4周龄早期CKD时起始6周。
主要发现
- 柠檬酸铁无论治疗起始时机均纠正敲除小鼠缺铁和贫血。
- 柠檬酸铁降低敲除小鼠循环FGF23水平和骨FGF23表达,早期CKD起始时降低更明显。
- 柠檬酸铁仅在早期CKD起始时降低血清磷酸盐。
- 柠檬酸铁无论起始时机均减轻收缩功能障碍,早期起始还减少肾纤维化和蛋白尿、改善肾功能并延长寿命。
临床怎么用
- 在CKD早期考虑使用柠檬酸铁可能有助于降低FGF23并延缓肾脏和心脏并发症进展。
局限性
- 本研究为小鼠模型实验,结果不能直接外推至人类CKD患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron deficiency, anemia, hyperphosphatemia, and increased fibroblast growth factor 23 (FGF23) are common and interrelated complications of chronic kidney disease (CKD) that are linked to CKD progression, cardiovascular disease and death. Ferric citrate is an oral phosphate binder that decreases dietary phosphate absorption and serum FGF23 concentrations while increasing iron stores and hemoglobin in patients with CKD. Here we compared the effects of ferric citrate administration versus a mineral sufficient control diet using the Col4a3 knockout mouse model of progressive CKD and age-matched wild-type mice. Ferric citrate was given to knockout mice for four weeks beginning at six weeks of age when they had overt CKD, or for six weeks beginning at four weeks of age when they had early CKD. Ten-week-old knockout mice on the control diet showed overt iron deficiency, anemia, hyperphosphatemia, increased serum FGF23, hypertension, decreased kidney function, and left ventricular systolic dysfunction. Ferric citrate rescued iron deficiency and anemia in knockout mice regardless of the timing of treatment initiation. Circulating levels and bone expression of FGF23 were reduced in knockout mice given ferric citrate with more pronounced reductions observed when ferric citrate was initiated in early CKD. Ferric citrate decreased serum phosphate only when it was initiated in early CKD. While ferric citrate mitigated systolic dysfunction in knockout mice regardless of timing of treatment initiation, early initiation of ferric citrate also reduced renal fibrosis and proteinuria, improved kidney function, and prolonged life span. Thus, initiation of ferric citrate treatment early in the course of murine CKD lowered FGF23, slowed CKD progression, improved cardiac function and significantly improved survival.
引用
- Francis C, Courbon G, Gerber C, et al. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. Kidney Int. 2019. PMID: 31668632. doi:10.1016/j.kint.2019.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。